Synonyms: Duvroq® | GSK-1278863 | GSK1278863 | Jesduvroq®
daprodustat is an approved drug (Japan (2020), FDA (2023))
Compound class:
Synthetic organic
Comment: Daprodustat is a compound which inhibits hypoxia inducible factor prolyl hydroxylase (HIF-PH) activity. HIF-PH inhibitors are being investigated as novel therapies for anemia, especially anemia caused by chronic kindney disease (CKD). It is hoped that HIF-PH inhibitors will provide a more effective alternative to the use of erythropoetin replacement therapy plus iron supplementation in CKD patients
|
|
References |
1. Bouchie A. (2013)
First-in-class anemia drug takes aim at Amgen's dominion. Nat Biotechnol, 31 (11): 948-9. [PMID:24213751] |
2. Dhillon S. (2020)
Daprodustat: First Approval. Drugs, 80 (14): 1491-1497. [PMID:32880805] |
3. Forristal CE, Levesque JP. (2014)
Targeting the hypoxia-sensing pathway in clinical hematology. Stem Cells Transl Med, 3 (2): 135-40. [PMID:24371328] |